Year: 2025

Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17 targeted ADC, with ongoing Phase 1 study in China Establised commercial leadership within excutive team with appointment of Brent S. Rice as Chief Commercial Officer Cash and investments of $305.4 million as of September 30, 2025 expected to fund operations into mid-2027NEWTOWN SQUARE, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) — ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: “AVBP”), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the third quarter ended September 30, 2025, and highlighted recent Company progress. “Our...

CONTINUED GROWTH AND TRANSFORMATIONAL ACQUISITION RESULT IN EXPANSION TO OVER 5.7 MILLION CONSUMERS(1) SERVED AND $6.6 BILLION IN MANAGED RECEIVABLES(2) ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) — Atlanticus Holdings Corporation (NASDAQ: ATLC) (Atlanticus, the Company, we, our or us), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced its financial results for the third quarter ended September 30, 2025. An accompanying earnings presentation is available in the Investors section of the Company’s website at www.atlanticus.com or by clicking here. Financial and Operating Highlights Third Quarter 2025 Highlights (all comparisons to the Third Quarter 2024)Completed acquisition of Mercury Financial LLC (“Mercury”)...

– Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 –  – Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration – – Ended 3Q25 with cash position of $229 million, maintaining runway into 2028 – LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported third quarter 2025 financial and operating results. “Voyager continues to seek out the optimal modalities for each neurotherapeutic target we pursue. During the third quarter, we shared initial preclinical data on our Voyager NeuroShuttle, a nonviral delivery platform with differentiated...

SINGAPORE, Nov. 10, 2025 (GLOBE NEWSWIRE) — Antalpha Platform Holding Company (NASDAQ: ANTA) (“Antalpha” or the “Company”) today announced its unaudited financial results for the quarter ended September 30, 2025. “Antalpha’s revenue grew 62% year over year in the third quarter. Our accelerating revenue growth and margin expansion underscores the scalability of our Prime lending platform, while capturing increasing demand from Bitcoin-mining financing and new lending scenarios, such as digital asset treasury financing,” said Paul Liang, chief financial officer of Antalpha. “A key driver of Antalpha’s growth is our exposure to the burgeoning crypto market, which plays to Antalpha Prime’s strength of leveraging over-collateralization and other risk-management measures to provide institutions liquidity to navigate...